KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has reached a commercial agreement with Cognetivity Neurosciences Ltd. (CSE: CGN; OTCQB: CGNSF; FWB: 1UB) for Cogneti. In addition, the Company and Cognetivity have signed a non-binding letter of intent to collaborate on mental health assessments and perform clinical trials inside Ketamine One’s clinic network.
Cognetivity is a software firm that has developed a cognitive testing platform that may be used in medical, commercial, and consumer settings. Ketamine One intends to deploy Cognetivity’s ICA across its network clinics in order to provide long-term monitoring of cognitive performance in patients with treatment-resistant depression and post-traumatic stress disorder, as per the conditions of the Agreement. In comparison to traditional pen-and-paper assessments, the ICA provides significant advantages to practitioners. The ICA is a five-minute computerized evaluation that is user-friendly and has no learning effect when repeated, making it ideal for long-term monitoring.
Because of its computerized design, the ICA is also capable of facilitating remote, self-administered testing. Individuals’ cognition will be assessed during their therapy, allowing doctors to quantify treatment efficacy while also empowering patients to take care of their own health and providing physicians with new data to adjust treatment and enhance outcomes.
The LOI will see Cognetivity and Ketamine One collaborate on developing and verifying next-generation mental health assessment tools to better the lives of sufferers, in addition to the ICA’s deployment in Ketamine One’s clinics. Cognetivity, according to the company, is a one-of-a-kind, technologically advanced assessment tool that may assist standardize in-clinic processes and provide a powerful analytical component to Ketamine One’s digital therapy platform.
It is well acknowledged that the treatment of such illnesses has a lot of room for improvement. Mental health disorders, more than cardiovascular disease or cancer, account for 28% of the worldwide burden of disability-adjusted life years among non-communicable diseases, according to the WHO. More than 12 billion working days are missed each year owing to mental health issues, costing the global economy US$16 trillion between 2011 and 2030. Anxiety disorder and depression treatments have an estimated addressable market size of US$238 billion.
